Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era

Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era

Background: Patients with hematological malignancies are at greater risk of severe COVID-19 and have been prioritized for COVID-19 vaccination. A significant proportion of them have an impaired vaccine response, both due to the underlying disease and to the treatments. Methods: We conducted a prospe...

Full description

Bibliographic Details
Main Authors: Jeremie Zerbit, Marion Detroit, Antoine Meyer, Justine Decroocq, Benedicte Deau-Fischer, Paul Deschamps, Rudy Birsen, Johanna Mondesir, Patricia Franchi, Elsa Miekoutima, Corinne Guerin, Rui Batista, Didier Bouscary, Lise Willems, Marguerite Vignon
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Viruses
Subjects:
COVID-19
hematology
immunotherapy
Online Access:https://www.mdpi.com/1999-4915/14/11/2377

Internet

https://www.mdpi.com/1999-4915/14/11/2377

Similar Items